Want to see CH:DOCM full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CH:DOCM Q2 2026 EPS Results
Actual EPS-CHF1.10
Consensus EPS―
Beat/Miss―
One Year Ago EPS-CHF2.11
CH:DOCM Q2 2026 Revenue Results
Actual RevenueCHF599.19M
Expected RevenueCHF291.10M
Beat/MissBeat by +CHF308.09M
YoY Revenue Growth+129.72%
Earnings Announcement Details
QuarterQ2 2026
Date08/19/2026
TimeBefore Open
Conference CallWednesday, August 19, 2026
CH:DOCM Upcoming Earnings
DocMorris's next earnings date is estimated for March 18, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed materially positive operational momentum: strong Rx acceleration, rapid Digital Services and TeleClinic growth, meaningful marketing and cost efficiencies, and a credible AI-driven cost-savings plan that supports improved margins and an accelerated guidance. Key risks persist—adjusted EBITDA remains negative, operating cash flow is still negative albeit improved, net debt rose, and regulatory/co-payment dynamics could exert pressure into 2027. Overall, the positive commercial and operational progress and tightened guidance outweigh the remaining near-term financial and regulatory headwinds.Company Guidance
Strong Rx growth and revenue acceleration
Rx revenue reached EUR 86.9m in Q2 '26 (doubling vs eRx start in Q2 '24), Q2 YoY growth +45.8% and H1 growth ~38.3%. Sequential Q1->Q2 Rx revenue +17.2% (EUR +12.6m). Active Rx customers +15.6% YoY in Q2 and +7.1% QoQ; Rx cohorts show much higher retention (latest cohorts 4.5x vs legacy paper cohorts and 2x vs first eRx cohorts).
Customer base expansion
Active customers expanded by ~1.1 million YoY to ~12.9m–13m, with TeleClinic contributing ~1.5m active users, supporting cross-sell and higher lifetime value.
Rapid Digital Services and TeleClinic momentum
Digital Services grew +71% in H1 and +80% in Q2; TeleClinic revenue +48% to EUR 17.6m in H1, treatment volumes +51% YoY to 1.3m, and TeleClinic EBITDA doubled YoY—showing scalable, high-margin platform growth.
AI-First strategy on track with material cost savings
AI-First execution expected to deliver >CHF 15m recurring annual net savings by end-2027; ~75% of savings to hit EBITDA, plus announced >100 FTE reductions and targeted annual CapEx savings >CHF 5m by end-2027.
Improving profitability and cash metrics
Adjusted EBITDA margin improved by 350 bps to -1.8% (YoY improvement); adjusted EBITDA improved ~CHF 18m YoY; operating cash flow improved by ~CHF 35m to -CHF 21.1m in H1 '26, demonstrating meaningful operational leverage.
Marketing and cost efficiency gains
Marketing expense decreased by CHF 14m YoY; marketing efficiency ratio improved by 310 bps and personnel expense ratio improved by 80 bps; distribution expense ratio declined by 10 bps—helping margin expansion.
Raised and narrowed FY'26 guidance; path to breakeven
External revenue growth guidance tightened and raised to 9–13% (from a wider range); adjusted EBITDA guidance narrowed to -CHF 10m to -CHF 17.5m (from -10m to -25m); company reconfirmed expectation of reaching EBITDA breakeven in 2026 and free cash flow breakeven in 2027.
High-margin Retail Media traction
dmr Advertising (Retail Media) exceeded EUR 10m net sales in H1 '26 with >100% YoY growth and delivered robust mid-double-digit EBITDA margins, providing a profitable, scalable revenue stream.
CH:DOCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed